Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: A phase III randomized placebo-controlled double-blind study

Diabetes Care

Volumn 21, Issue 5, 1998, Pages 822-827

  Wieman, T Jeffery ^a,c   Smiell, Janice M ^b   Su, Yachin ^b  

^a University of Louisville School of Medicine   (United States)

^b R W JOHNSON PHARMACEUTICAL RES I   (United States)

^c Alliant Medical Pavilion   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; PLATELET DERIVED GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EDEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOMYELITIS; PAIN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN ULCER; TOPICAL DRUG ADMINISTRATION; ULCER HEALING; WOUND DRESSING;

ADMINISTRATION, TOPICAL; AGED; ANTICOAGULANTS; CHRONIC DISEASE; DEMOGRAPHY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; RECOMBINANT PROTEINS; REFERENCE VALUES; TREATMENT OUTCOME;

EID: 0031734833     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.5.822     Document Type: Article

References (15)

1. Reiber GE: Diabetic foot care: financial implications and practice guidelines. Diabetes Care 15 (Suppl. 1):29-31, 1992
2. Wieman TJ, Griffiths GD, Polk HC Jr, Ashmore JD, Ryan B, Das SK, Classen J, Johnson C: Management of diabetic midfoot ulcers. Ann Surg 215:627-632, 1992
3. Palumbo PJ, Melton LJ III: Peripheral vascular disease and diabetes. In Diabetes in America. Harris MI, Hamman RF, Eds. Washington, DC, U.S. Government Printing Office, 1985, p. 1-21
4. Reiber GE: The epidemiology of diabetic foot problems. Diabet Med 13:S6-S11, 1996
5. United States Department of Health and Human Services: National Diabetes Fact Sheet: national estimates and general information on diabetes in the United States. Press release, 1 November 1997
6. Apelqvist J, Ragnarson-Tennvall G, Larsson J, Persson U: Long-term costs for foot ulcers in diabetic patients in a multidisciplinary setting. Foot Ankle Int 16:388-394, 1995
7. Mustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause J, Bear M, Serdar CM, Pierce GF: A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers, Arch Surg 129:213-219, 1994
8. Robson MC, Thomason A, Pierce GF, Phillips LG, Robson LE: Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339:23-25, 1992
9. Steed DL, the Diabetic Ulcer Study Group: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vase Surg 21:71-81, 1995
10. Pressure ulcers prevalence, cost and risk assessment: consensus development conference statement: The National Pressure Ulcer Advisory Panel. Decubitus 2:24-28, 1989
11. Dermal wounds: pressure sores: philosophy of the IAET. J Enterostomal Ther 15:4-17, 1988
12. Meyer-Ingold W: Wound therapy: growth factors as agents to promote healing. Trends Biotechnol 11:387-392, 1993
13. Bennett NT, Schultz GS: Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg 165:728-737, 1993
14. Bennett NT, Schultz GS: Growth factors and wound healing. Part II. Role in normal and chronic wound healing. Am J Surg 166:74-81, 1993
15. Steed DL, Donohoe D, Webster MW, Lindsley L, the Diabetic Ulcer Study Group: Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg 183:61-64, 1996